β-内酰胺类抗生素过敏与长期临床结局的关联
该研究为美国宾夕法尼亚州西部一家区域医疗系统的纵向回顾性队列研究,纳入2007—2008年因脓毒症、肺炎或尿路感染就诊的20092例患者,其中4211例(21.0%)记录有β-内酰胺类过敏,随访至死亡或2018年底。采用广义估计方程分析显示,β-内酰胺类过敏与死亡风险无显著关联(OR 1.02,95%CI 0.96-1.09),但与MRSA感染(OR 1.44,95%CI 1.36-1.53)、VRE感染(OR 1.18,95%CI 1.05-1.32)及3种耐药感染合并率(OR 1.33,95%CI 1.30-1.36)升高相关;与艰难梭菌感染、2期和3期AKI及3期AKI无显著关联。作者认为,卫生系统应重视过敏记录的准确性,减少不必要的β-内酰胺类规避。
要点
- 记录有β-内酰胺类过敏的患者远期死亡风险未显著升高(OR 1.02,95%CI 0.96-1.09)。
- β-内酰胺类过敏与MRSA感染风险升高相关(OR 1.44,95%CI 1.36-1.53)。
- β-内酰胺类过敏与VRE感染风险升高相关(OR 1.18,95%CI 1.05-1.32)。
- β-内酰胺类过敏与3种耐药感染合并率升高相关(OR 1.33,95%CI 1.30-1.36),与艰难梭菌感染无显著关联(OR 1.04,95%CI 0.94-1.16)。
- β-内酰胺类过敏与2期和3期AKI(OR 1.02,95%CI 0.96-1.10)及3期AKI(OR 1.06,95%CI 0.98-1.14)无显著关联。
适用人群与场景
- 2007—2008年在单一区域医疗系统因脓毒症、肺炎或尿路感染就诊并纳入电子健康记录分析的患者。
- 共20092例,平均(SD)年龄62.9(19.7)岁,女性12231例(60.9%);黑人3513例(17.5%),白人15358例(76.4%),其他种族1221例(6.0%)。
诊断标准与关键阈值
- 暴露定义为患者电子健康记录过敏栏目中记录有任何β-内酰胺类抗生素,在最早观察到的医疗就诊时评估。
研究设计与关键结果
- 研究类型为纵向回顾性队列研究,在宾夕法尼亚州西部单一区域医疗系统开展,纳入20092例患者,其中记录有β-内酰胺类过敏者4211例(21.0%),无记录者15881例(79.0%),随访至死亡或2018年底。
- 主要终点全因死亡(数据来自社会保障死亡索引)与β-内酰胺类过敏无显著关联(OR 1.02,95%CI 0.96-1.09)。
- β-内酰胺类过敏与MRSA感染风险升高相关(OR 1.44,95%CI 1.36-1.53),与VRE感染风险升高相关(OR 1.18,95%CI 1.05-1.32),与3种耐药感染合并率升高相关(OR 1.33,95%CI 1.30-1.36)。
- β-内酰胺类过敏与艰难梭菌感染无显著关联(OR 1.04,95%CI 0.94-1.16)。
- β-内酰胺类过敏与2期和3期AKI(OR 1.02,95%CI 0.96-1.10)及3期AKI(OR 1.06,95%CI 0.98-1.14)无显著关联。
证据类型、等级与局限
- 证据类型:纵向回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,卫生系统应强调准确的过敏记录,并减少不必要的β-内酰胺类规避。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: β-lactam (BL) allergies are the most common drug allergy worldwide, but most are reported in error. BL allergies are also well-established risk factors for adverse drug events and antibiotic-resistant infections during inpatient health care encounters, but the understanding of the long-term outcomes of patients with BL allergies remains limited.
OBJECTIVE: To evaluate the long-term clinical outcomes of patients with BL allergies.
DESIGN, SETTING, AND PARTICIPANTS: This longitudinal retrospective cohort study was conducted at a single regional health care system in western Pennsylvania. Electronic health records were analyzed for patients who had an index encounter with a diagnosis of sepsis, pneumonia, or urinary tract infection between 2007 and 2008. Patients were followed-up until death or the end of 2018. Data analysis was performed from January 2022 to January 2024.
EXPOSURE: The presence of any BL class antibiotic in the allergy section of a patient's electronic health record, evaluated at the earliest occurring observed health care encounter.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, derived from the Social Security Death Index. Secondary outcomes were defined using laboratory and microbiology results and included infection with methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, or vancomycin-resistant Enterococcus (VRE) and severity and occurrence of acute kidney injury (AKI). Generalized estimating equations with a patient-level panel variable and time exposure offset were used to evaluate the odds of occurrence of each outcome between allergy groups.
RESULTS: A total of 20 092 patients (mean [SD] age, 62.9 [19.7] years; 12 231 female [60.9%]), of whom 4211 (21.0%) had BL documented allergy and 15 881 (79.0%) did not, met the inclusion criteria. A total of 3513 patients (17.5%) were Black, 15 358 (76.4%) were White, and 1221 (6.0%) were another race. Using generalized estimating equations, documented BL allergies were not significantly associated with the odds of mortality (odds ratio [OR], 1.02; 95% CI, 0.96-1.09). BL allergies were associated with increased odds of MRSA infection (OR, 1.44; 95% CI, 1.36-1.53), VRE infection (OR, 1.18; 95% CI, 1.05-1.32), and the pooled rate of the 3 evaluated antibiotic-resistant infections (OR, 1.33; 95% CI, 1.30-1.36) but were not associated with C difficile infection (OR, 1.04; 95% CI, 0.94-1.16), stage 2 and 3 AKI (OR, 1.02; 95% CI, 0.96-1.10), or stage 3 AKI (OR, 1.06; 95% CI, 0.98-1.14).
CONCLUSIONS AND RELEVANCE: Documented BL allergies were not associated with the long-term odds of mortality but were associated with antibiotic-resistant infections. Health systems should emphasize accurate allergy documentation and reduce unnecessary BL avoidance.
参考来源
- Gray MP, Kellum JA, Kirisci L, et al. Long-Term Outcomes Associated With β-Lactam Allergies. JAMA Netw Open. 2024. PMID: 38758551. doi:10.1001/jamanetworkopen.2024.12313
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。